Status:
TERMINATED
Inhaled Steroids for the Treatment of Early Pediatric Acute Respiratory Distress Syndrome
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Acute Respiratory Distress Syndrome
Eligibility:
All Genders
30-18 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to show that inhaled steroids in patient with PARDS can decrease the days on mechanical ventilator measured by ventilator-free days,to improve the oxygenation index (OI) o...
Eligibility Criteria
Inclusion
- Pediatric patients older than 30 days and up to 18 years of age admitted to the PICU with a diagnosis of PARDS enrolled within 72 hours of diagnosis.
- Patients requiring invasive mechanical ventilation.
- Criteria of PARDS as defined by the Pediatric Acute Lung Injury Consensus Conference (PALICC), on June 2015 in Pediatric Critical Care Journal
Exclusion
- Patients with diffuse alveolar hemorrhage.
- Patients terminally ill with limitation of care or in hospice care.
- Patients receiving inhaled steroids or systemic steroids as chronic therapy before admission.
- Patients with high dose systemic steroids for anti-inflammatory purposes. The investigators will not exclude patients receiving hydrocortisone for shock.
Key Trial Info
Start Date :
February 4 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2020
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04064684
Start Date
February 4 2020
End Date
March 30 2020
Last Update
July 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030